Evidence brief · Capacity

PSA screening, free PSA and MRI

Who took part in screening trials, where the 25% free-PSA cutoff came from and when MRI can help avoid a biopsy.

By Andre Heeg, Dr. med., Dr. med. dent.Created November 10, 2026
Share or cite this brief
LinkedInEmail

Key Takeaways

A PSA result raises two different questions. One is whether screening benefits a group over decades. The other is what to do about the result in front of a patient today.

  • In the European screening trial, one fewer man died of prostate cancer per 456 men invited to repeated screening over 23 years. The main analysis covered men aged 55 to 69 at entry. [1]
  • The original 25% free-PSA cutoff came from men aged 50 to 75 with a total PSA of 4 to 10 ng/mL and a benign examination. Interpreting the percentage requires the person’s age, total PSA and examination history. [2]

Download the evidence pack (Markdown) ↓

Common questions

When do guidelines suggest discussing a first PSA?

The AUA allows a baseline test at ages 45 to 50 and recommends earlier discussion for higher-risk groups. The EAU generally starts at 50, at 45 for certain family histories or African ancestry, and at 40 for BRCA2 carriers. Health and life expectancy matter. [3] [4]

When is a repeat test appropriate?

The EAU recommends repeating a PSA of 3 to 10 ng/mL in an asymptomatic man before further investigations. The guideline discusses using the same laboratory under similar conditions. Symptoms or a concerning examination can change the next step. [4]

What does a low percentage of free PSA mean?

In the Catalona study, the 25% cutoff detected 95% of cancers and spared about 20% of unnecessary biopsies. The percentage alone does not give someone outside the study population their personal chance of cancer. [2]

Can a negative MRI spare someone a biopsy?

In PRECISION, 28% of men in the MRI arm avoided biopsy under the trial protocol. In practice, PSA density, family history and other signs of risk help determine whether monitoring after a negative scan is reasonable. [5] [4]

What did the micro-ultrasound trial establish?

OPTIMUM compared image-guided biopsy methods. Micro-ultrasound met its noninferiority criterion for detecting clinically significant cancer. Participants underwent biopsy, so the trial could not show how safe it would be to skip one after a negative scan. [6]

What are the tradeoffs after a screening diagnosis?

In ProtecT, deaths from prostate cancer were uncommon over 15 years in all three groups. Metastases were more frequent with active monitoring than with surgery or radiotherapy. The trial used a monitoring protocol from an earlier era. [7]

References

  1. Roobol, M. J., de Vos, I. I., Månsson, M., et al. (2025). European study of prostate cancer screening: 23-year follow-up. New England Journal of Medicine, 393(17), 1669–1680.
  2. Catalona, W. J., Partin, A. W., Slawin, K. M., Brawer, M. K., Flanigan, R. C., Patel, A., Richie, J. P., deKernion, J. B., Walsh, P. C., Scardino, P. T., Lange, P. H., Subong, E. N., Parson, R. E., Gasior, G. H., Loveland, K. G., & Southwick, P. C. (1998). Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial. JAMA, 279(19), 1542–1547.
  3. Lin, D. W., Carlsson, S., Filson, C. P., Kim, S. K., Kirkby, E., Konety, B. R., Purysko, A. S., & Souter, L. H. (2026). Updates to early detection of prostate cancer: AUA/SUO guideline (2026). The Journal of Urology, 215(5), 491–501.
  4. Cornford, P., Tilki, D., van den Bergh, R. C. N., et al. (2026). EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer (limited text update, March 2026). European Association of Urology.
  5. Kasivisvanathan, V., Rannikko, A. S., Borghi, M., Panebianco, V., Mynderse, L. A., Vaarala, M. H., et al. (2018). MRI-targeted or standard biopsy for prostate-cancer diagnosis. New England Journal of Medicine, 378(19), 1767–1777.
  6. Kinnaird, A., Luger, F., Cash, H., Ghai, S., Urdaneta-Salegui, L. F., Pavlovich, C. P., et al. (2025). Microultrasonography-guided vs MRI-guided biopsy for prostate cancer diagnosis: The OPTIMUM randomized clinical trial. JAMA, 333(19), 1679–1687.
  7. Hamdy, F. C., Donovan, J. L., Lane, J. A., et al. (2023). Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. New England Journal of Medicine, 388(17), 1547–1558.

Related reading

For informational and educational purposes only. This page does not provide individual medical advice, diagnosis, or treatment. Read the full medical disclaimer.

Under Load · Every Sunday

One health claim, checked. Every Sunday.

Join 20,000+ readers across platforms. The Field Guide arrives with your confirmation.